Completed
A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)
NCT04341389
- Conditions
- COVID-19, Coronaviridae Infections, Coronavirus Infections, +9 more
- Locations
-
- Hubei Provincial Center for Disease Control and Prevention Wuhan, Hubei, China